Volume 10, Issue 03, March 2024,
Publish Date: 04-03-2024
Doi https://doi.org/10.55640/ijmsdh-10-03-18

International Journal of Medical Science and Dental Health **(Open Access)**

AUTOIMMUNE DISORDERS UNRAVELED: THE INTERPLAY BETWEEN GENETICS AND THE IMMUNE SYSTEM

ESRA HASSAN ABD ALI[1], HUSSAIN OWAID MOHAMMED[2]

[1]Basic Science Department, Dentistry college, Mustansiriyah University, Baghdad-Iraq

[2]Oral surgery and Periodontology Department, Dentistry college, Mustansiriyah University, Baghdad-Iraq

ABSTRACT

Autoimmune diseases are a group of disorders that have an abnormal immune response against the owner's tissues. Another key feature in the pathogenesis of these diseases is an interaction between genetics and environment. Although the emergence of a number of recent genomic technologies has simplified establishing many susceptibility genes and loci that determine an inherited predisposition to autoimmunity, the goal of this review article is to explore the element of complexity that stems from correlation between genetics and immunity when focusing autoimmune diseases. It provides major genetic differences that define immune cell activity, mechanisms related to the regulation of self-tolerance and inflammatory reactions. Also, the review describes epigenetic modifications that could modify gene expression and behaviour of immune systems causing disease development or progression. In this chapter, using GWAS as well as other types of genetic studies we address how these recent advances in genetics have improved our understanding of disease mechanisms and enabled the development of novel strategies for personalizing therapeutic interventions. This paper further explores the opportunities such genetic findings present in creating predictive models for disease risk assessment and as a prescription to personalized medicine. The understanding and control of autoimmunity will greatly benefit from unravelling the genetic complexities involved in these conditions.

INTRODUCTION

A collection of diseases referred to as autoimmune disorders is defined by an abnormal immune response directed against the body's healthy cells and tissues which results in chronic inflammation and tissue damage. Such conditions are known to impact multiple organs and systems such as joints, skin, thyroid gland pancreas among others. Autoimmune diseases are complex and multifactorial, resulting from the interaction of predisposition caused due to genetic factors environmental triggers [(1)].

The immune system has been designed in such a way that it can identify the foreign agents and then eliminate them to make sure that the body remains healthy. But in autoimmune people, the immune system cannot identify self and non-self-antigens. Alternatively, it erroneously attacks normal cells and tissues as if they were invaders, leading to an immune reaction [(2, 3)].

Autoimmune reactions are largely genetically determined. Some genes are linked to the occurrence of these conditions. Numerous genetic variants and susceptibility loci related to autoimmune diseases have been discovered with the help of GWAS. These genetic factors affect immune cell functions, the self-tolerance mechanisms regulation and immunity equilibrium [4].

Besides genetic determinants, environmental factors can also lead to the development and severity of autoimmune diseases. Autoimmune responses may be provoked by various influences such as infections, hormonal alterations caused due to the presence of some drugs or chemicals and life-style parameters associated with dietary habits and smoking [5, 6].

To learn the causes of autoimmune diseases, it is necessary to comprehend how genetics and immunology are related. The genomic technologies have given significant genetic revelations to these diseases. Selecting particular genes, pathways and signalling molecules that link with autoimmunity allows scientists to create better treatment methods by treating each individual separately [7].

This review article will discuss issues about the relationship between genetics and the immune system in autoimmune disorder since this phenomenon is rather complex. Now we are going to look into genetic vulnerability concerning these disorders, the impact of environmental factors and epigenetic modifications that regulate gene expression in autoimmunity.

Genetic Predisposition in Autoimmunity

Genetic factors play a major contributor to autoimmune disorders. Depending on research, a family history of autoimmune disorders increases the chance to developing such conditions. This means that particular genes are connected with autoimmunity susceptibility [8].

GWAS is essential for the identification of specific genetic variants that are linked to autoimmune diseases. These researches also find out the genetics of thousands autoimmune people and contrast them against healthy ones. This method enables the researchers to find several genetic variants and susceptibility loci predisposed by different autoimmune diseases [9].

One of the major findings in GWAS is that certain immune system regulation and function genes are involved. For example, HLA genes are strongly linked to a number of autoimmune diseases that differences in the same may change immune response from self-antigens leading into auto immunity [10].

Besides HLA genes, other non-HLA implicate in autoimmune disorders. These genes are implicated in different immune-related pathways that include T cell activation, B cell development, cytokine signaling and the proliferation of various cells involved with immunity. Such differences in these genes can lead to impairment of the immune system's equilibrium and autoimmune disease [11].

It should be emphasized that genetic predisposition does not suffice to induce autoimmune dysfunction. Environmental factors are very important in promoting the expression of these diseases on genetically predisposed individuals. There are several possible interactions between factors such as infections, hormonal changes exposure to certain drugs or chemicals and lifestyle influences like diet and smoking with genetic components that can lead to the development of autoimmune reactions [12].

The genetic component of autoimmunity leads to better knowledge regarding the mechanisms involved in diseases and potential sites for treatment. It makes it possible for researchers to generate more targeted approaches, in terms of diagnosis, treatment and prevention. This can improve results due to the identification of higher-risk individuals based on their genetic profile and subsequent preventive strategies or individual modifications according to specific genetic subtypes [7, 12, 13].

Autoimmune Disorder	Associated Genetic Variants	Function/Pathway Implicated	Environmental Triggers
Rheumatoid Arthritis	HLA-DRB1	Antigen presentation	Smoking, periodontal disease
Systemic Lupus Erythematosus	IRF5, STAT4, TNFAIP3	Type I interferon signaling, T cell activation, NF-κB pathway	UV exposure, infections
Multiple Sclerosis	HLA-DRB1, IL2RA, CD40	T cell activation, B cell development, immune regulation	Vitamin D deficiency, viral infections
Type 1 Diabetes	HLA-DQB1, INS	Antigen presentation, insulin production	Viral infections, early childhood diet
Hashimoto's Thyroiditis	CTLA4, HLA-DR3	Immune regulation, antigen presentation	Iodine intake, stress
Celiac Disease	HLA-DQ2, HLA-DQ8	Gluten intolerance, T cell activation	Gluten consumption
Psoriasis	IL23R, IL12B	Th17 cell differentiation, cytokine signaling	Stress, skin injury
Inflammatory Bowel Disease	NOD2, IL23R	Intestinal barrier function, immune response	Gut microbiota, smoking
Graves' Disease	HLA-B8, CTLA4	Immune regulation, thyroid function	Stress, smoking
Vitiligo	TYR, PTPN22	Melanocyte function, immune response	Autoimmune triggers

Table 1. *(Genetic Variants, Functions, and Environmental Triggers in Autoimmune Disorders.)*

Environmental Triggers and Gene-Environment Interactions

Although genetic predisposition is important in the development of many autoimmune disorders, environmental variables also play a role in initiating and exacerbating many conditions. Environmental stimuli can interact with predisposing genes, enhancing or initiating autoimmune responses [5].

Environmental Trigger	Gene-Environment Interaction

Infections	Some infections associated with specific genetic variants may cause an autoimmune reaction that causes Rheumatoid Arthritis, Systemic Lupus Erythematosus and Type 1 Diabetes [14-16].
Hormonal Factors	Underlying dysfunction of the immune system, which may lead to the formation of systemic lupus erythematosus and rheumatoid arthritis among other people with genetic variants, is sometimes caused by hormonal changes [17, 18].
Environmental Exposures	People with some of these mutations may develop autoimmune diseases such as drug-induced lupus and other related diseases after exposure to certain drugs or chemicals. Toxic substances[19] .
Dietary Factors	People with certain genetic variants can develop immune responses as a result of exposure to certain components of the diet; This leads to the development of autoimmune disorders such as celiac disease and Hashimoto's thyroiditis [20, 21].
Lifestyle Factors	Those with certain genetic copies are at risk of exacerbation of autoimmune disorders affecting conditions such as rheumatoid arthritis, psoriasis, or Graves' disease due to lifestyle factors such as smoking, physical trauma, and others [22, 23].
Gut Microbiota	Individuals with certain genetic variants develop small intestine dysbiosis that contributes to the regulation of the immune system that promotes autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis [24].
UV Exposure	It has been seen that UV radiation may be the causative or aggravating agent for autoimmune diseases like Systemic Lupus Erythematosus and Vitiligo among people with specific genetic differences [25].
Vaccinations	Though these are not as clearly defined, there were some isolated cases when vaccination caused the autoimmune diseases. Rather, the advantages of vaccinations in regard to stunting infectious diseases overrule any potential adverse consequences that their induction may bring about on autoimmunity [26-28].
Epigenetic Modifications	Epigenetic alterations of gene expression and immune function can be triggered by environmental factors that may result in autoimmune diseases [29].
Gene-Environment Interactions	Genetic predisposition and environmental triggers are equally important to understanding autoimmune disease etiology. Gene environment interactions regulate disease susceptibility, onset and severity, underscoring the need for a holistic approach to understanding these disorders that considers both genetic as well as environmental influences [5].

Table 2. *(Environmental Triggers, Gene-Environment Interactions, and Implicated Autoimmune Disorders.)*

Key Genetic Variants and Susceptibility Loci

Through genome-wide association studies (GWAS), several genetic variants and susceptibility loci related to autoimmune diseases have been identified. These essential genetic variants influence the occurrence and evolution of these diseases, providing insights into autoimmune mechanisms.

1. HLA Genes: The HLA complex that is found on chromosome 6 has a large number of genes in form proteins that participate to identify self and non-self-antigens from the immune system. Some variants of the HLA genes, especially those in alleles such as DRB1 , DQB and Q 2 /8 have been strongly associated with different autoimmune diseases which include Rheumatoid Arthritis Systemic Lupus Erythematosus Others like Type 1 Diabetes Celiac disease Multiple Sclerosis. However, these variants are associated with antigen presentation and T cell activation which is crucial for immune responses [30].
2. Non-HLA Genes: Besides HLA genes, non-HLA genetic variations have also been associated with the risk of autoimmune diseases. For instance, the variation within IRF5, STAT4 TNFAIP3 IL23R PTPN22 and CTLA4 genes have been linked to an increased risk of developing Systemic Lupus Erythematosus Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease among autoimmune diseases. These non-HLA genetic variants are also related to various different immune processes such as cytokine signaling and activation of immune cells regulation [15, 31, 32].
3. Cytokine Genes: Autoimmune diseases have been shown to be correlated with variants of genes responsible for encoding cytokines, which are important signaling molecules within the immune system. For instance, some of the genetic variants in IL2RA gene have been connected to Multiple Sclerosis which shows susceptibility while others from the genes like IL12B and IL 23R are linked with Psoriasis and Inflammatory Bowel Disease pathogenesis. This is because these cytokine gene variants affect immunocyte development and the signaling of immune cell pathways, resulting in dysregulated immune response to autoimmunity [33].
4. Epigenetic Regulators: Epigenetic modifications can affect gene expression and immune function. Autoimmune diseases have been associated to the mutations observed in epigenetic regulation genes such as DNA methyltransferases and histone modifying enzymes. These genetic variants lead to changes in expression of genes and immune cell function through epigenetic means that may help explain disease development [34].

Epigenetic Mechanisms in Autoimmune Regulation

There are several epigenetic modifications that contribute significantly to the regulation of gene expression as well as maintenance of immunological functions. The processes involving DNA methylation, histone modifications and non-coding RNA regulation have been suggested in the development of autoimmune diseases. Immune cell maturation, activation, and reaction to self-antigens can be influenced by epigenetic changes that lead to the disturbances in immune processes observed as autoimmunity.

1. DNA Methylation: DNA methylation is a process that involves the introduction of -CH3 groups to particular sites on CpG sequences and suppresses gene transcription. In autoimmune diseases, nonstandard DNA methylation patterns have been found in

immune cells that cause gene expression anomalies. However, hypermethylation of regulatory sites in immune tolerance and immunocyte activity genes can lead to the repression of protective genes as well as irregularity [35].

2. Histone Modifications: The histone modifications such as acetylation, methylation, phosphorylation and ubiquitination change the structure of chromatin to alter gene availability. These changes may affect the activation or suppression of certain immunoregulatory genes. Dysregulated histone modifications have been linked to differentiation of immune cells, cytokine production and inflammatory response in autoimmune diseases [36].
3. Non-Coding RNAs: Post-transcriptional regulation of gene expression involves non-coding RNAs, which include microRNA and long non-coding RNAs. Autoimmune responses can be facilitated by such regulatory RNAs that target genes and pathways associated with the immune response. Deglobalization of non-coding RNAs has been linked with autoimmune disease by affecting immune cell function and inflammation [37].
4. Environmental Influence on Epigenetic Modifications: Epigenetic changes caused by environmental factors including infections, hormonal shifts as well dietary components and toxins or pollutants can affect the work of immune system. Such environmental impacts of epigenetic modifications may promote the initiation or aggravation in autoimmune responsiveness among genetically predisposed individuals [38, 39].

Immune System Dysregulation and Loss of Self-Tolerance

The immune system has been engineered to be able to differentiate between self and non-self-antigens, defending its host against foreign invaders but tolerate the host's own tissues. With autoimmune diseases, this delicate balance is destroyed and the immune system becomes mis regulated due to loss of self-tolerance. This disintegration occurs due to several factors: genetic susceptibility, environmental agents and malfunctioning of the immune cells.

Factor	Description
Genetic Predisposition	Autoimmune disease-associated genetic variants affect immune cell generation, activation and reactivity to self-antigens thereby interfering with the ability of the immune system to identify and tolerate itself.
Environmental Triggers	Environmental factors act in conjunction with genetic predisposition to initiate and potentiate the autoimmune responses, inciting inflammatory processes, interfering immunological cell function while distorting immune self-tolerance.
Dysregulated Immune Cell Function	Non-normative activation, proliferation and cytokine generation by immune cells like T cell's, B cell's antigen presenting along with self-recognition of an individual would often stimulate the inflammatory responses against a fellow human being.
Loss of Immune Tolerance	The failure to maintain central and peripheral tolerance leads to the presence of auto-reactive T cells which cause destruction on self-tissue thus perpetuating an autoimmune response.

Inflammatory Responses	The chronic inflammation and tissue damage that result from dysregulated immune cell function, combined with self-tolerance loss, continue to perpetuate autoimmune disease by contributing toward the development of hyperactive responses against self-antigens.

Table 3. *(Factors Contributing to Immune System Dysregulation and Loss of Self-Tolerance.)*

The Role of the Human Leukocyte Antigen (HLA) Complex

The HLA complex plays a significant role in the identification of self and non-self-antigens by the immune system. This involves a wide range of genes coding for proteins associated with immune responsiveness found on chromosome 6. The HLA molecules play a very crucial role in antigen presentation to T cells, which then serve as key actors of initiating immune response and maintaining immunological tolerance. The HLA complex is highly polymorphic that has many allele variants which determine the frequency and sensitivity to autoimmune disease development in a person.

1. Antigen Presentation: HLA molecules especially class I (HLA-A, B, C) and II(DR,-DP,& DQ produce antigen presentation to T cells. Intracellular antigens are presented by HLA class I molecules to CD8+ cytotoxic T cells while extracellular antigens are presented via HLA-II molecules, on the other hand, to CD4' helper T cell. This step is crucial for starting particular immune responses against pathogens and cancer cells [40-43].
2. Immune Regulation: HLA molecules play an important role in immune response regulation and self-tolerance preservation. HLA molecules play a significant role in the selection of T lymphocytes, as well as peripheral tolerance mechanisms that are aimed at preventing autoimmunity. Polymorphisms in HLA genes may affect the spectrum of presented antigens and magnitude of subsequent T cell activation, thereby contributing to immune tolerance as well as increased risk for autoimmune disorders [44].
3. Autoimmune Diseases: Variations of HLA very strongly correlate with risk for autoimmune diseases. For instance, certain HLA-DRB1 alleles are associated with Rheumatoid Arthritis while the others include HLA-DQB1 and HLA-DQ2/ DQ8 alleles that have relation to Celiac Disease. These variants regulate antigen presentation and T cell activation that can lead to autoimmune responses [10].
4. Transplantation: The degree of polymorphism in the HLA complex is a fundamental factor to consider when performing organ and tissue transplants. HLA antigen matching between the donors and recipients is important for minimizing graft rejection/graft-versus host disease risks. The broad HLA alleles necessitate thorough hla typing to determine potential donor-recipient matches [30].
5. Pharmacogenomics: Adverse drug reactions are also linked to HLA polymorphisms in pharmacogenomics. Some HLA variants are linked to drug hypersensitivity reactions that include severe cutaneous adverse reactions and drugs-induced liver injury. Knowing individual HLA genotypes could shed light on personalized medicine and minimize the risk of adverse drug reactions [45].

HLA complex is a major factor contributing to immune recognition and response, as well it determines autoimmune disease susceptibility, transplantation results and drug hypersensitivity. This vital part of

immune regulation and antigen presentation in health's as well as diseases highlights the importance placed on it in terms of research into immunology and personalized medicine.

Non-HLA Genes and Pathways in Autoimmune Disease.

Besides the HLA complex, non-HLa genes and pathways are also involved in autoimmune disease ethology. A wide range of non-HLA genetic variants associated with autoimmunity has been identified through GWAS; this makes it possible to illuminate key molecular pathways that are fundamental in terms of immune dysregulation and loss self-tolerance [11].

Immune Cell Activation and Signalling: Many of the non-HLA genes involved in autoimmune diseases affect immune cell activation, signalling pathways and cytokine production. For instance, polymorphisms in genes encoding proteins involved in T cell activation (such as CD28 and CTLA4), B cell development (like BANK1) or cytokine signalling operations like IL23R and IL12B have been described to be associated with an increased susceptibility risk of all kinds of autoimmune diseases [11].

Innate Immunity and Pattern Recognition: Links between autoimmune mechanisms and genes that are associated with innate immune responses, as well as pattern recognition receptor pathways. Polymorphisms of genes encoding pattern recognition receptors such as TLRs and NOD2, or molecules in the regulation innate immune response e.g., IRF5 contribute to impulse innate immunity towards development auto-inflammatory events [46].

Regulatory T Cell Function: Regulatory T cells (Tregs) are a key player in helping to maintain immune tolerance and prevent autoimmunity. Other non-HLA variants associated with Treg development, function and suppressive activity have also been linked to autoimmune diseases. Immune tolerance mechanisms are influenced by genes associated with Treg differentiation such as FOXP3, immunosuppressive cytokine production (e.g., IL2RA), and one involved in the stability of Treg cells –IL 2/LL1) [47].

Autoantibody Production: A key characteristic of autoimmune diseases is the development of autoantibodies, which are related to non-HLA genetic mutations. Most of the genes are observed to be involved in B cell activation (for instance, PTPN22), antibody production [for example BLK], and immune complex clearance for autoantibodies targeting self- antigens [12].

Cellular Homeostasis and Apoptosis: Cellular homeostasis, apoptosis and self-antigen release lead to the initiation of autoimmune response. Variants in genes controlling cellular homeostasis (such as BANK1) or apoptosis pathways, including TNFAIP3, can influence the risk of autoimmune diseases by affecting immune clearance and protection system [48].

Non-HLA Gene / Pathway	Implicated Function	Associated Autoimmune Disorders
CD28	T cell activation	Rheumatoid Arthritis, Type 1 Diabetes, Systemic Lupus Erythematosus
CTLA4	Immune regulation	Rheumatoid Arthritis, Graves' Disease, Type 1 Diabetes

BANK1	B cell development	Systemic Lupus Erythematosus, Rheumatoid Arthritis
IL23R	Cytokine signaling	Psoriasis, Inflammatory Bowel Disease
IL12B	Th1/Th17 cell differentiation	Psoriasis, Inflammatory Bowel Disease
TLRs	Pattern recognition receptors	Systemic Lupus Erythematosus, Rheumatoid Arthritis
NOD2	Innate immunity	Crohn's Disease, Blau Syndrome
IRF5	Regulation of innate immune responses	Systemic Lupus Erythematosus, Rheumatoid Arthritis
FOXP3	Regulatory T cell function	Immune dysregulation leading to various autoimmune diseases
IL2RA	Treg development	Type 1 Diabetes, Multiple Sclerosis
PTPN22	B cell activation	Rheumatoid Arthritis, Type 1 Diabetes
BLK	Antibody production	Systemic Lupus Erythematosus, Rheumatoid Arthritis
Fcγ Receptors	Immune complex clearance	Systemic Lupus Erythematosus, Rheumatoid Arthritis
BANK1	Cellular homeostasis	Systemic Lupus Erythematosus, Rheumatoid Arthritis
TNFAIP3	Apoptotic pathways	Rheumatoid Arthritis, Systemic Lupus Erythematosus

Table 4. *(Non-HLA Genes and Pathways in Autoimmunity.)*

Integrating Genomics with Immune Pathway Analysis

However, the combination of genomics with immune pathway analysis emerges as a potent strategy to reveal molecular mechanisms driving autoimmune diseases and find disease-modifying treatment targets. Through the integration of genomic data along with immune pathway analysis, enable researchers to define the intricate relationships between genetic variants, functional changes in affected cells and corrupted signalling routes that drive autoimmunity.

1. **Genomic Profiling:** The high-throughput genomic technologies, with whole-genome sequencing, exome sequencing and GWAS as examples are capable of profiling genetic variants associated to the autoimmune diseases. These methods allow understanding

the genetic structure of autoimmunity, revealing specific genes, loci and pathways associated with predisposition to disease development and its course [49].

2. **Immune Cell Function:** At the same time, immune pathway analysis describes how activation; differentiation and effector functions occur in relation to autoimmune diseases. This encompasses determining the profiles of expression for immune-related genes, cytokines, chemokine and signaling molecules to define both how dysregulated innate immune responses underlie autoimmunity [50].
3. **Network-Based Approaches:** The integration of genomics with immune pathway analysis utilizes network-based strategies that simulate the dynamics among genetic variants, immunological signaling routes and regulatory systems. Building gene regulatory networks and protein-protein interaction network is one of the ways that help researchers to find out key nodes, hub genes as well as dysregulated pathways involved with autoimmune diseases [51].
4. **Functional Genomics:** Functional genomics techniques like CRISPR/Cas9 gene editing and RNA interference (RNAi) help in analyzing the functional effect of genetic variants on immunological cell activity, and disease development. Such approaches allow analysis of the causal link between genetic aberrations and deregulated immune responses in autoimmunity [52].
5. **Biomarker Discovery:** The use of genomic data integration with immune pathway analysis makes it easier to find potential biomarkers for autoimmune disorders. As a result, researchers can develop diagnostic and prognostic biomarkers to stratify patients for disease management and treatment response prediction based on gene expression signatures cytokine profiles or immune cell phenotypes [53].
6. **Therapeutic Target Identification:** The combination of genomics with immune pathway analysis helps in the discovery of new drug targets for autoimmune diseases. With targeted immune pathways and genetic predispositions to autoimmunity, researchers can focus on where drug development potential targets are as well as precision medicine intervention points [54].

Future Direction	Description
Single-Cell Genomics	Advancements in single-cell sequencing technologies offer the potential to dissect the heterogeneity of immune cell populations in autoimmune diseases at an unprecedented resolution.
Epigenome-Wide Association Studies (EWAS)	Integration of epigenomic data with genetic analyses through EWAS can provide insights into the role of epigenetic modifications in autoimmune diseases.
Longitudinal Studies	Longitudinal genomic studies of dynamic changes in genetic, epigenetic and transcriptomic profiles over time may reveal temporal evolutionary trends in autoimmune diseases.

Multi-Omics Integration	Integrating genomics with other omics data, such as transcriptomics, proteomics, and metabolomics, enables a comprehensive understanding of the molecular networks underlying autoimmune diseases.
Systems Immunogenetics	Systems immunogenetics approaches aim to integrate genetic variation with immune system function and environmental influences to elucidate the complex interplay contributing to autoimmunity.
Precision Medicine Strategies	Precision medicine initiatives driven by genetic insights promise to customize treatments for individual patients according to their genotypes.
Therapeutic Target Prioritization	Leveraging genetic discoveries to prioritize therapeutic targets for drug development and repurposing can expedite the translation of genomic insights into clinical applications.

Table 5. (Future Directions in Genetic Research of Autoimmune Diseases.)

CONCLUSION

In summary, the genetics review in autoimmune diseases sheds a central role of genomics to unravel underlying genetic complexities as well immune pathogenesis and environmental etiologies causing these conditions. Combinatorial approaches between advanced genomic technologies and immune pathway analysis, epigenomics studies, and multi-omics strategies have implications to deliver new insights about disease etiology; biomarker discovery; therapeutic targets. Other developments that have a tremendous potential for personalized medicine as well as the development of individual-tailored drugs are genetic improvement including single cell genomics, longitudinal studies and precision medicine agendas. Using these emerging methods, scientists can achieve a clear comprehension of autoimmune diseases that will result in superior clinical diagnostics and prognostics along with optimal patient-focused interventions.

REFERENCES

1. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S238-47.
2. Vojdani A, Vojdani E, Rosenberg AZ, Shoenfeld Y. The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens. Pathophysiology. 2022;29(2):243-80.
3. Janeway Jr CA, Travers P, Walport M, Shlomchik MJ. Autoimmune responses are directed against self antigens. Immunobiology: The Immune System in Health and Disease 5th edition: Garland Science; 2001.
4. Lucas CL, Lenardo MJ. Identifying genetic determinants of autoimmunity and immune dysregulation. Curr Opin Immunol. 2015;37:28-33.
5. Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, et al. Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci. 2016;73(24):4611-22.

6. Mohammed ZJ, Sharba MM, Mohammed AA. THE EFFECT OF CIGARETTE SMOKING ON HAEMATOLOGICAL PARAMETERS IN HEALTHY COLLEGE STUDENTS IN THE CAPITAL, BAGHDAD. European Journal of Molecular & Clinical Medicine
7. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol. 2009;27:363-91.
8. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med. 2013;11:73.
9. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2):R116-21.
10. Cruz-Tapias P, Castiblanco J, Anaya J-M. HLA association with autoimmune diseases. Autoimmunity: From Bench to Bedside [Internet]: El Rosario University Press; 2013.
11. Anaya J-M, Castiblanco J, Lessard CJ. Non-HLA genes and autoimmune diseases. Autoimmunity: From Bench to Bedside [Internet]: El Rosario University Press; 2013.
12. Pisetsky DS. Pathogenesis of autoimmune disease. Nature Reviews Nephrology. 2023;19(8):509-24.
13. Mohammed M, Al-Saadi MS, Al-Karawi AS. An examination of the seroprevalence of torch infections and their correlation with adverse reproductive outcomes in females exhibiting a bad obstetric history.
14. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023;13(3).
15. Al-Karawi AS, Alawssi YF, Khadhum MK. Immunological Insights into Rheumatoid Arthritis: A Comprehensive Review of Diagnosis and Assessment Approaches. African Journal of Advanced Pure and Applied Sciences (AJAPAS). 2023:151-9.
16. Kready HO, Mohammed M, Salem M, Al-Karwi AS. SCREENING AND DIAGNOSIS OF BETA-THALASSEMIA DEPENDING ON HBA2 AND BLOOD FILM IN BAGHDAD CITY. World. 2023;2(6).
17. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med. 2017;23(7):615-35.
18. Karawi A, Kadhim A. Exploring the role of autoantibodies in Iraqi females with polycystic ovary syndrome. J Adv Biotechnol Exp Ther. 2024;7(1):147.
19. Pollard KM, Hultman P, Kono DH. Toxicology of autoimmune diseases. Chem Res Toxicol. 2010;23(3):455-66.
20. Alajeeli FS, Al-Karawi AS, Ali MM. The Immunological Significance of Medicinal Plants in Disease Control and Prevention in Humans. Al-Salam Journal for Medical Science. 2023;2(2):13-9.
21. Ashok T, Patni N, Fatima M, Lamis A, Siddiqui SW. Celiac Disease and Autoimmune Thyroid Disease: The Two Peas in a Pod. Cureus. 2022;14(6):e26243.
22. Júnior DST. Environmental and individual factors associated with protection and predisposition to autoimmune diseases. Int J Health Sci (Qassim). 2020;14(6):13-23.
23. Al-Karawi AS, Atoom AM, Al-Adwan SM, Adwan SW. Assessment of selected biochemical and immunological parameters after treatment by Cosmetic Procedures. Journal of Population Therapeutics and Clinical Pharmacology. 2023;30(2):201-13.
24. Mousa WK, Chehadeh F, Husband S. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Front Immunol. 2022;13:906258.
25. Estadt SN, Maz MP, Musai J, Kahlenberg JM. Mechanisms of Photosensitivity in Autoimmunity. J Invest Dermatol. 2022;142(3 Pt B):849-56.

26. Olivieri B, Betterle C, Zanoni G. Vaccinations and Autoimmune Diseases. Vaccines (Basel). 2021;9(8).
27. MOHAMMED M, Mousa D, Tareq Jafaar Al-Jindeel H, Al-Karawi S. Latent and reactivation Cytomegalovirus (CMV) infection can cause severe fetal sequelae despite pre-conceptional immunity.
28. Al-Karawi AS, Abid FM, Mustafa A, Abdulla M. Revealing the Urinary Microbiota in Prostate Cancer: A Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application. Al-Salam Journal for Medical Science. 2024;3(1):45-54.
29. Mazzone R, Zwergel C, Artico M, Taurone S, Ralli M, Greco A, et al. The emerging role of epigenetics in human autoimmune disorders. Clinical Epigenetics. 2019;11(1):34.
30. Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007;48(1):11-23.
31. Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):170-9.
32. Ahmed MH, Karkush SI, Ali SA, Mohammed AA. Phytochemicals: a new arsenal in drug discovery. International Journal of Medical Science and Dental Health. 2024;10(01):29-44.
33. Gutierrez-Arcelus M, Rich SS, Raychaudhuri S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat Rev Genet. 2016;17(3):160-74.
34. Surace AEA, Hedrich CM. The Role of Epigenetics in Autoimmune/Inflammatory Disease. Front Immunol. 2019;10:1525.
35. Araki Y, Mimura T. The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape. J Immunol Res. 2016;2016:6290682.
36. Liu R, Wu J, Guo H, Yao W, Li S, Lu Y, et al. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm (2020). 2023;4(3):e292.
37. De Benedittis G, Ciccacci C, Latini A, Novelli L, Novelli G, Borgiani P. Emerging Role of microRNAs and Long Non-Coding RNAs in Sjögren's Syndrome. Genes (Basel). 2021;12(6).
38. Ho SM, Johnson A, Tarapore P, Janakiram V, Zhang X, Leung YK. Environmental epigenetics and its implication on disease risk and health outcomes. Ilar j. 2012;53(3-4):289-305.
39. Al-Azzawi MA, Maftool AJ, Al-Shimary AA, Mohammed AA. A Comprehensive Review of Vitamin D3: Metabolism, Functions, and Clinical Implications. International Journal of Medical Science and Dental Health. 2023;9(12):37-46.
40. Van Kaer L. Major histocompatibility complex classI-restricted antigen processing and presentation. Tissue antigens. 2002;60(1):1-9.
41. Mohammed AA, Mahmoud HQ, Mhana RS. ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF BREAST CANCER: A SYSTEMATIC REVIEW. World. 2023;2(6).
42. Mahmoud HQ, Mhana RS, Mohammed AA. Therapeutic options and management approach on thalassemia an overview. International Journal of Medical Science and Dental Health. 2024;10(01):17-28.
43. Gavali LV, Mohammed AA, Al-Ogaili MJ, Gaikwad SH, Kulkarni M, Das R, et al. Novel terephthalaldehyde bis (thiosemicarbazone) Schiff base ligand and its transition metal complexes as antibacterial Agents: Synthesis, characterization and biological investigations. Results in Chemistry. 2024;7:101316.
44. Crux NB, Elahi S. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol. 2017;8:832.

45. Kloypan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C. A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals (Basel). 2021;14(11).
46. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240-73, Table of Contents.
47. Lourenço EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity. 2011;44(1):33-42.
48. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F, et al. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr Pharm Des. 2008;14(3):253-68.
49. Knight JC. Genomic modulators of the immune response. Trends Genet. 2013;29(2):74-83.
50. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-24.
51. Ko DK, Brandizzi F. Network-based approaches for understanding gene regulation and function in plants. Plant J. 2020;104(2):302-17.
52. Ford K, McDonald D, Mali P. Functional Genomics via CRISPR-Cas. J Mol Biol. 2019;431(1):48-65.
53. Fenton KA, Pedersen HL. Advanced methods and novel biomarkers in autoimmune diseases - a review of the recent years progress in systemic lupus erythematosus. Front Med (Lausanne). 2023;10:1183535.
54. Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol. 2010; 28:535-71.